TY - JOUR
T1 - Epilepsy in tuberous sclerosis complex
T2 - Findings from the TOSCA Study
AU - the TOSCA Consortium and TOSCA Investigators
AU - Nabbout, Rima
AU - Belousova, Elena
AU - Benedik, Mirjana P.
AU - Carter, Tom
AU - Cottin, Vincent
AU - Curatolo, Paolo
AU - Dahlin, Maria
AU - D´Amato, Lisa
AU - d'Augères, Guillaume Beaure
AU - de Vries, Petrus J.
AU - Ferreira, José C.
AU - Feucht, Martha
AU - Fladrowski, Carla
AU - Hertzberg, Christoph
AU - Jozwiak, Sergiusz
AU - Lawson, John A.
AU - Macaya, Alfons
AU - Marques, Ruben
AU - O'Callaghan, Finbar
AU - Qin, Jiong
AU - Sander, Valentin
AU - Sauter, Matthias
AU - Shah, Seema
AU - Takahashi, Yukitoshi
AU - Touraine, Renaud
AU - Youroukos, Sotiris
AU - Zonnenberg, Bernard
AU - Jansen, Anna
AU - Kingswood, John C.
AU - Shinohara, Nobuo
AU - Horie, Shigeo
AU - Kubota, Masaya
AU - Tohyama, Jun
AU - Imai, Katsumi
AU - Kaneda, Mari
AU - Kaneko, Hideo
AU - Uchida, Yasushi
AU - Endo, Shoichi
AU - Inoue, Yoshikazu
AU - Uruno, Katsuhisa
AU - Serdaroglu, Ayse
AU - Yapici, Zuhal
AU - Anlar, Banu
AU - Altunbasak, Sakir
AU - Lvova, Olga
AU - Valeryevich Belyaev, Oleg
AU - Agranovich, Oleg
AU - Vladislavovna Levitina, Elena
AU - Vladimirovna Maksimova, Yulia
AU - Fattal-Valevski, Aviva
N1 - Publisher Copyright:
© 2018 The Authors. Epilepsia Open published by Wiley Periodicals Inc. on behalf of International League Against Epilepsy.
PY - 2019/3
Y1 - 2019/3
N2 - Objective: To present the baseline data of the international TuberOus SClerosis registry to increase disease Awareness (TOSCA) with emphasis on the characteristics of epilepsies associated with tuberous sclerosis complex (TSC). Methods: Retrospective and prospective patients’ data on all aspects of TSC were collected from multiple countries worldwide. Epilepsy variables included seizure type, age at onset, type of treatment, and treatment outcomes and association with genotype, seizures control, and intellectual disability. As for noninterventional registries, the study protocol did not specify any particular clinical instruments, laboratory investigations, or intervention. Evaluations included those required for diagnosis and management following local best practice. Results: Epilepsy was reported in 83.6% of patients (1852/2216) at baseline; 38.9% presented with infantile spasms and 67.5% with focal seizures. The mean age at diagnosis of infantile spasms was 0.4 year (median <1 year; range <1-30 years) and at diagnosis of focal seizures was 2.7 years (median 1 year; range <1-66 years). A total of 1469 patients (79.3%) were diagnosed with epilepsy <2 years. The rate of infantile spasms was higher in patients with a TSC2 mutation than in patients with a TSC1 mutation (47.3% vs 23%). ɣ-aminobutyric acid (GABA)ergic drugs were the most common treatment modality for both infantile spasms (78.7%) and focal seizures (65.5%). Infantile spasms and focal seizures were controlled in 76.3% and 58.2% of patients, respectively. Control of seizures was associated with lower rates of intellectual disability in both groups. Significance: This registry reports the largest international cohort of patients with TSC. Findings confirmed the typical onset pattern of infantile spasms and other focal seizures in the first 2 years of life, and the high rates of infantile spasms in patients with TSC2 mutation. Our results underscored the occurrence of focal seizures at all ages, including an onset that preceded emergence of infantile spasms. Seizure control was shown to be associated with lower rates of intellectual disability but did not preclude the presence of intellectual disability.
AB - Objective: To present the baseline data of the international TuberOus SClerosis registry to increase disease Awareness (TOSCA) with emphasis on the characteristics of epilepsies associated with tuberous sclerosis complex (TSC). Methods: Retrospective and prospective patients’ data on all aspects of TSC were collected from multiple countries worldwide. Epilepsy variables included seizure type, age at onset, type of treatment, and treatment outcomes and association with genotype, seizures control, and intellectual disability. As for noninterventional registries, the study protocol did not specify any particular clinical instruments, laboratory investigations, or intervention. Evaluations included those required for diagnosis and management following local best practice. Results: Epilepsy was reported in 83.6% of patients (1852/2216) at baseline; 38.9% presented with infantile spasms and 67.5% with focal seizures. The mean age at diagnosis of infantile spasms was 0.4 year (median <1 year; range <1-30 years) and at diagnosis of focal seizures was 2.7 years (median 1 year; range <1-66 years). A total of 1469 patients (79.3%) were diagnosed with epilepsy <2 years. The rate of infantile spasms was higher in patients with a TSC2 mutation than in patients with a TSC1 mutation (47.3% vs 23%). ɣ-aminobutyric acid (GABA)ergic drugs were the most common treatment modality for both infantile spasms (78.7%) and focal seizures (65.5%). Infantile spasms and focal seizures were controlled in 76.3% and 58.2% of patients, respectively. Control of seizures was associated with lower rates of intellectual disability in both groups. Significance: This registry reports the largest international cohort of patients with TSC. Findings confirmed the typical onset pattern of infantile spasms and other focal seizures in the first 2 years of life, and the high rates of infantile spasms in patients with TSC2 mutation. Our results underscored the occurrence of focal seizures at all ages, including an onset that preceded emergence of infantile spasms. Seizure control was shown to be associated with lower rates of intellectual disability but did not preclude the presence of intellectual disability.
KW - TOSCA
KW - epilepsy
KW - registry
KW - tuberous sclerosis complex
UR - http://www.scopus.com/inward/record.url?scp=85062434615&partnerID=8YFLogxK
U2 - 10.1002/epi4.12286
DO - 10.1002/epi4.12286
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
AN - SCOPUS:85062434615
SN - 2470-9239
VL - 4
SP - 73
EP - 84
JO - Epilepsia Open
JF - Epilepsia Open
IS - 1
ER -